Search Results - Torben Plesner

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens by Katrine Fladeland Iversen, Line Nederby, Thomas Lund, Torben Plesner

    Published in Clinical Hematology International (2022-08-01)
    Get full text
    Article


  2. 2

    The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study by Agoston Gyula Szabo, Katrine Fladeland Iversen, Sören Möller, Torben Plesner

    Published in Clinical Hematology International (2019-08-01)
    Get full text
    Article


  3. 3

    Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? by Torben Plesner, Niels W. C. J. van de Donk, Paul G. Richardson

    Published in Cells (2020-02-01)
    Get full text
    Article


  4. 4

    Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report by Katrine F. Iversen, Paw C. Holdgaard, Birgitte Preiss, Charlotte G. Nyvold, Torben Plesner

    Published in Haematologica (2019-09-01)
    Get full text
    Article


  5. 5

    The Incidence and Timing of Blood Cultures in Multiple Myeloma – Results from a Retrospective, Single Center, Real-World Study by Agoston Gyula Szabo, Katrine Fladeland Iversen, Flemming Schønning Rosenvinge, Sören Möller, Torben Plesner

    Published in Clinical Hematology International (2020-08-01)
    Get full text
    Article


  6. 6

    Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59 by Kieran Brennan, Katrine F. Iversen, Alfonso Blanco-Fernández, Thomas Lund, Torben Plesner, Margaret M. Mc Gee

    Published in Cells (2022-10-01)
    Get full text
    Article


  7. 7

    Baseline bone involvement in multiple myeloma – a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography... by Maja Hinge, Kristian T. Andersen, Thomas Lund, Henrik B. Jørgensen, Paw C. Holdgaard, Tina E. Ormstrup, Lone L. Østergaard, Torben Plesner

    Published in Haematologica (2016-10-01)
    Get full text
    Article


  8. 8

    Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment by Maja Hinge, Kristian T Andersen, Thomas Lund, Henrik B Jørgensen, Paw C Holdgaard, Tina E Ormstrup, Lone L Østergaard, Torben Plesner

    Published in Haematologica (2016-10-01)
    Get full text
    Article


  9. 9

    Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly D... by Kristian T. Andersen, Maja Hinge, Agoston Gyula Szabo, Erik Segel, Tina Ormstrup, Paw C. Holdgaard, Niels Pallisgaard, Gitte Kerndrup, Torben Plesner

    Published in Clinical Hematology International (2020-01-01)
    Get full text
    Article


  10. 10

    P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB by Ida H. Hiemstra, Kim Santegoets, Maarten Janmaat, Wessel Ten Hagen, Rosanna Sanchez, Lauren Brady, Sieto Bosgra, Marije Overdijk, Jenny Chen, Katrine Fladeland Iversen, Torben Plesner, Esther Breij

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  11. 11

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma by Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen Miller, Eunpi Cho, Fredrik Schjesvold

    Published in Clinical Hematology International (2023-01-01)
    Get full text
    Article


  12. 12

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma by Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser

    Published in Blood Advances (2017-10-01)
    Get full text
    Article


  13. 13

    The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network by Niels W.C.J. van de Donk, Antonio Palumbo, Hans Erik Johnsen, Monika Engelhardt, Francesca Gay, Henrik Gregersen, Roman Hajek, Martina Kleber, Heinz Ludwig, Gareth Morgan, Pellegrino Musto, Torben Plesner, Orhan Sezer, Evangelos Terpos, Anders Waage, Sonja Zweegman, Hermann Einsele, Pieter Sonneveld, Henk M. Lokhorst

    Published in Haematologica (2014-06-01)
    Get full text
    Article


  14. 14

    Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO) by Jesus San-Miguel, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari

    Published in Haematologica (2020-04-01)
    Get full text
    Article


  15. 15

    The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG) by Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Michael R. Clausen, Ilske Oschlies, Matthias Ritgen, Marco Herling, Kirsten Fischer, Hartmut Döhner, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Michael Hallek, Sebastian Böttcher, Wolfram Klapper, Barbara Eichhorst

    Published in HemaSphere (2024-07-01)
    Get full text
    Article


  16. 16

    Insights on Multiple Myeloma Treatment Strategies by María-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, Meral Beksac, Joan Bladé, Mario Boccadoro, Michele Cavo, Michel Delforge, Meletios A. Dimopoulos, Thierry Facon, Catarina Geraldes, Hartmut Goldschmidt, Roman Hájek, Markus Hansson, Krzysztof Jamroziak, Merav Leiba, Tamás Masszi, Larisa Mendeleeva, Michael O’Dwyer, Torben Plesner, Jesús F. San-Miguel, Christian Straka, Niels W.C.J. van de Donk, Kwee Yong, Samo Zver, Philippe Moreau, Pieter Sonneveld

    Published in HemaSphere (2019-02-01)
    Get full text
    Article


  17. 17

    Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) by Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek, Barbara Eichhorst

    Published in HemaSphere (2020-02-01)
    Get full text
    Article


Search Tools: